title: The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview.
abstract: Aggressive histological subtypes of thyroid cancer are rare and have a poor prognosis. The most important aggressive subtypes of thyroid cancer are Hürthle cell carcinoma (HCTC) and anaplastic and poorly differentiated carcinoma (ATC and PDTC). The American Thyroid Association recently published guidelines for the management of patients with ATC, but no specific guidelines have been done about HCTC. We performed an overview of the literature about the role of Fluorine-18-Fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (FDG-PET or PET/CT) in aggressive histological subtypes of thyroid cancer. Only few original studies about the role of FDG-PET or PET/CT in HCTC, PDTC, and ATC have been published in the literature. FDG-PET or PET/CT seems to be useful in staging or followup of invasive and metastatic HCTC. FDG-PET or PET/CT should be used in patients with ATC in initial staging and in the followup after surgery to evaluate metastatic disease. Some authors suggest the use of FDG-PET/CT in staging of PDTC, but more studies are needed to define the diagnostic use of FDG-PET/CT in this setting. Limited experience suggests the usefulness of FDG-PET or PET/CT in patients with more aggressive histological subtypes of DTC. However, DTC presenting as radioiodine refractory and FDG-PET positive should be considered aggressive tumours with poor prognosis.
authors: Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Via Ospedale 12, 6500 Bellinzona, Switzerland.
authors: Giorgio
authors: G
authors: Treglia
authors: Salvatore
authors: S
authors: Annunziata
authors: Barbara
authors: B
authors: Muoio
authors: Massimo
authors: M
authors: Salvatori
authors: Luca
authors: L
authors: Ceriani
authors: Luca
authors: L
authors: Giovanella
references: J Clin Oncol. 2009 Jun 1;27(16):2697-704
references: 19380450
references: Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2277-85
references: 20694463
references: Thyroid. 2009 Jun;19(6):565-612
references: 19469690
references: Clin Nucl Med. 2011 Dec;36(12):e180-5
references: 22064103
references: Clin Nucl Med. 2012 Feb;37(2):121-7
references: 22228332
references: Eur Arch Otorhinolaryngol. 2013 May;270(6):1783-7
references: 23053387
references: Clin Nucl Med. 1996 Nov;21(11):831-3
references: 8922841
references: Endocr Relat Cancer. 2011 Jan 13;18(1):159-69
references: 21118976
references: Ann Nucl Med. 2009 Feb;23(2):131-6
references: 19225935
references: Cancer. 2008 Jul 1;113(1):48-56
references: 18484584
references: J Nucl Med. 2006 Aug;47(8):1260-6
references: 16883003
references: Ann Surg Oncol. 2006 Apr;13(4):453-64
references: 16474910
references: Cancer. 2000 Jul 1;89(1):202-17
references: 10897019
references: J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41
references: 19837916
references: Clin Nucl Med. 2008 Dec;33(12):834-7
references: 19033781
references: J Thyroid Res. 2012;2012:198313
references: 22007340
references: Thyroid. 2012 Nov;22(11):1187-90
references: 23050785
references: Thyroid. 2008 Nov;18(11):1179-81
references: 18925842
references: J Nucl Med. 2003 Sep;44(9):1402-6
references: 12960183
references: Thyroid. 2008 Jul;18(7):713-9
references: 18630999
references: Endocr Pathol. 2004 Winter;15(4):319-27
references: 15681856
references: Hell J Nucl Med. 2011 May-Aug;14(2):188-9
references: 21761030
references: J Clin Oncol. 2001 May 15;19(10):2616-25
references: 11352953
references: Minerva Endocrinol. 2008 Dec;33(4):341-57
references: 18923370
references: Head Neck. 2012 May;34(5):626-31
references: 21850699
references: Thyroid. 2012 Nov;22(11):1104-39
references: 23130564
references: J Clin Oncol. 2003 Sep 1;21(17):3226-35
references: 12947056
references: Eur Radiol. 1999;9(5):975-8
references: 10370003
references: Clin Nucl Med. 2003 Sep;28(9):728-31
references: 12972993
references: J Oncol. 2010;2010:
references: 20847957
references: Surgery. 2001 Dec;130(6):1028-34
references: 11742333
references: Thyroid. 2009 Nov;19(11):1167-214
references: 19860577
references: Eur J Nucl Med. 1999 Dec;26(12):1547-52
references: 10638405
references: Expert Rev Endocrinol Metab. 2012 Jan;7(1):35-43
references: 30736109
references: Nuklearmedizin. 1995 Aug;34(4):127-34
references: 7675641
references: Cancer Control. 2005 Oct;12(4):254-60
references: 16258498
references: Semin Nucl Med. 2011 Mar;41(2):121-38
references: 21272686
references: Thyroid. 2002 Feb;12(2):155-61
references: 11916285